Bayer acquires Asklepios to advance gene therapies

By The Science Advisory Board staff writers

October 26, 2020 -- Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical (AskBio), a U.S.-based biotechnology company specializing in gene therapies.

AskBio is investigating preclinical and clinical adeno-associated virus (AAV) candidates to explore treatments for neuromuscular, cardiovascular, metabolic, and central nervous system diseases. The acquisition adds AAV therapies research to Bayer's portfolio.

Bayer agreed to pay $2 billion in upfront consideration and up to another $2 billion of success-based milestone payments to acquire AskBio. Bayer will fully own AskBio's gene therapy platform, including the company's intellectual property portfolio and its contract development and manufacturing organization.

The acquisition strengthens Bayer's commitment to cell and gene therapy, according to the company. Bayer also said the deal also complements its 2019 acquisition of BlueRock Therapeutics, which allowed the firm to create platforms that affect multiple therapeutic areas.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here